|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03759 PHARMARON
Nominal 
13.340 +0.340 (+2.615%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 11,537,996 | 12.387% | 10,266,288 | 7,443,770 | 5,133,597 | 3,757,160 |
| Cost of Sales | (7,443,176) | 14.211% | (6,517,012) | (4,771,726) | (3,217,484) | (2,425,459) |
| Gross Profit | 4,094,820 | 9.216% | 3,749,276 | 2,672,044 | 1,916,113 | 1,331,701 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (35,825) | 69.329% | (21,157) | (10,269) | (14,823) | (5,495) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (2,084) | -93.844% | (33,851) | 71,845 | (24,565) | (7,303) | |
| Profit / (Loss) before Taxation | 1,837,887 | 10.291% | 1,666,391 | 1,910,996 | 1,319,370 | 632,550 | |
| Taxation | (256,106) | -18.504% | (314,254) | (290,919) | (172,378) | (101,878) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 19,315 | -14.029% | 22,467 | 40,952 | 25,391 | 16,518 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,601,096 | 16.477% | 1,374,604 | 1,661,029 | 1,172,383 | 547,190 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 148,649 | 12.528% | 132,099 | 18,666 | (50,210) | 72,862 |
| Depreciation & Amortisation | 1,008,588 | 31.659% | 766,063 | 577,673 | 438,016 | 374,582 |
| Directors' Emoluments | 6,916 | -0.561% | 6,955 | 21,653 | 13,637 | 8,963 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 90.330 | 16.555% | 77.500 | 93.253 | 65.889 | 36.818 |
| DPS (cts) | 20.000 | -- | 20.000 | 20.000 | 13.333 | 6.667 |
| Dividend Payout Ratio (%) | 22.141% | -- | 25.806% | 21.447% | 20.236% | 18.107% |
| Cash flow per share ($) | 1.554 | -- | 1.209 | 1.156 | 1.390 | 1.421 |
| NBV per share ($) | 6.917 | -- | 5.793 | 5.558 | 4.962777 | 4.345526 |
| Remarks: | Real time quote last updated: 29/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,113,403 |
| %Change | 41.638% |
| EPS / (LPS) | RMB 0.628 |
| NBV Per Share (¥) | RMB 7.280 |